1-6 of 6
Natasha Schuier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)

Free
Marc Raaijmakers, Hartmut Döhner, Dimitri Breems, John Byrd, Konstanze Döhner, Jordi Esteve, Bjørn Gjertsen, Patrycja Gradowska, Gerwin A. Huls, Ain Kaare, Heeje Kim, Hitoshi Kiyoi, Mika Kontro, Janusz Krawczyk, Vladimir Lazarevic, Andrea Lenartova, Alice Mims, Jeannine Refos, Christoph Röllig, Anika Schrade, Karolina Sikorska, Alexandre Theocharides, Peter Valk, Adriano Venditti, Jianxiang Wang, Andrew Wei, Agnieszka Wierzbowska, Andrius Zucenka, Lucille Ferrante, Christina Drenberg Guttke, Angélique Langlois, Christina Loefgren, Kathryn Packman, Prathap Nagaraja Shastri, Natasha Schuier, Meena Thayu, Danielle Trancucci, Bob Lowenberg, Lars Bullinger
Journal: Blood
Blood (2025) 146 (Supplement 1): 1654.
https://doi.org/10.1182/blood-2025-1654
Published: 2025
Journal Articles

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Free
Elias Jabbour, David Sallman, Debbie Briseno-Toomey, Christina Drenberg Guttke, Xiaojun Huang, Richard Dillon, Lucille Ferrante, Takayuki Ikezoe, Angélique Langlois, Christina Loefgren, Boaz Nachmias, Ayelet Nelson, Kathryn Packman, Prathap Nagaraja Shastri, Christian Recher, Gail Roboz, Natasha Schuier, Meena Thayu, Danielle Trancucci, Athena Zuppa, Christoph Röllig, Andrew Wei
Journal: Blood
Blood (2025) 146 (Supplement 1): 3429.
https://doi.org/10.1182/blood-2025-3429
Published: 2025
Journal Articles

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Free
Carsten Utoft Niemann, Talha Munir, Carolyn Owen, George Follows, Jose-Angel Hernandez Rivas, Ohad Benjamini, Ann Janssens, Mark-David Levin, Tadeusz Robak, Martin Simkovic, Sergey Voloshin, Vladimir I. Vorobyev, Loic Ysebaert, Natasha Schuier, Kurt Baeten, Ping Xu, Nguyet Tran, Bennett S. Levitan, Claire Kavanagh, Arnon P. Kater
Journal: Blood
Blood (2024) 144 (Supplement 1): 1871.
https://doi.org/10.1182/blood-2024-203269
Published: 2024
Journal Articles

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Free
Carol Moreno, Talha Munir, Carolyn Owen, George Follows, Jose-Angel Hernandez Rivas, Ohad Benjamini, Ann Janssens, Mark-David Levin, Tadeusz Robak, Martin Simkovic, Sergey Voloshin, Vladimir I. Vorobyev, Munci Yagci, Loic Ysebaert, Qianya Qi, Emma Smith, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater
Journal: Blood
Blood (2023) 142 (Supplement 1): 634.
https://doi.org/10.1182/blood-2023-177713
Published: 2023
Journal Articles

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Free
Carsten U Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Österborg, Tadeusz Robak, Martin Šimkovič, Sergey Voloshin, Vladimir I. Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianaya Qi, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (Supplement 1): 228–230.
https://doi.org/10.1182/blood-2022-156070
Published: 2022
Journal Articles

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

Free
Tahla Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Österborg, Tadeusz Robak, Martin Simkovic, Don Stevens, Sergey Voloshin, Vladimir I. Vorobyev, Munchi Yagci, Loic Ysebaert, Qianaya Qi, Andrew Steele, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater
Journal: Blood
Blood (2021) 138 (Supplement 1): 70.
https://doi.org/10.1182/blood-2021-148666
Published: 2021